Emerging agents to combat complicated and resistant infections: focus on ceftobiprole - Wikidata - wikimedia - TriplyDB

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

http://www.wikidata.org/entity/Q35026567

about

Pseudomonas aeruginosa ventilator-associated pneumonia management Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

P2860

Q26768365-EEB796D9-3EEC-4BF3-9CA7-ED28480C92D4 Q28071882-3819AB0E-3626-46AD-8D8E-5F88BC8E8981 Q38958278-9DED2CDF-AFAE-43F6-A2FA-9BB55A091450

P2860

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

http://www.wikidata.org/entity/Q35026567

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

@ast

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

@en

type

label

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

@ast

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

@en

prefLabel

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

@ast

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

@en

P1433

Q35026567-AB416806-956F-4E6F-95F0-DC16684B774A

P1476

Q35026567-E2371E7A-03AC-49BD-8DD4-42550448A2C3

P2093

Q35026567-649930FB-1BBC-4B72-9892-4E3BA5A95876

P2860

Q35026567-07F33489-4435-46C3-958A-787BF2317C19

Q35026567-0AEE3B78-7240-4FC2-83C4-68B191DA68CD

Q35026567-0DAF47B5-F660-49E0-9BCA-862DDB2C0FD5

Q35026567-0FBB859C-E5DC-4649-9099-794C8BBE18D2

Q35026567-151301BD-A103-444A-804E-600771150B35

Q35026567-1B238646-792A-45E9-9DD4-884638A36483

Q35026567-23A8E5FA-D7DD-4BDC-9872-9DE330AEFBFC

Q35026567-24921D02-3161-4CF7-965A-FF4CF8A2452F

Q35026567-256CEC95-1B95-40FF-9656-FCC0712B6A90

Q35026567-28AE28DF-D60B-43FD-992D-73A8B3B8E7C9

P304

Q35026567-C41CA61F-5658-48B6-B6FE-6F7DAB2BA749

P31

Q35026567-8D74B8DF-215B-4958-B52F-E12724D294D9

P356

Q35026567-534ACD1E-06D7-4A05-BF5D-82E71353570A

P407

Q35026567-C3B9C3CB-65C5-4242-BC81-3B70A448EDBD

P478

Q35026567-33411169-6D33-4C4B-8CF0-283CF5EA825D

P50

Q35026567-16456517-6733-4E9F-A666-BFC71562B60C

P577

Q35026567-B7A4C363-A241-498F-A7EB-DCAB71AFEBFC

P698

Q35026567-3EE79982-8C48-4EEB-BA54-FE31CC69F8CC

P932

Q35026567-3F0C5DE1-6820-4459-95F5-0075B51858BD

P356

P1433

Infection and Drug Resistance

P1476

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole

@en

P2093

César Bustos

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci

Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole.

Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.

Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used.

Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.

Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains

Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.

P304

5-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IDR.S3681

http://www.w3.org/2001/XMLSchema#string

P407

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Jose L Del Pozo

P577

2010-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21694889

http://www.w3.org/2001/XMLSchema#string

P932

3108737

http://www.w3.org/2001/XMLSchema#string